Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Status:
Terminated
Trial end date:
2016-07-18
Target enrollment:
Participant gender:
Summary
Nelarabine has shown significant activity in patients with T-cell malignancies. This study
will determine the safety and maximum tolerated dose of the combination of nelarabine,
cyclophosphamide and etoposide in patients with first bone marrow relapse of T-ALL, or first
relapse of T-LL.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Therapeutic Advances in Childhood Leukemia Consortium